2472-15-3

Upstream product

• 116906-99-1 7-benzyloxy-3,4-dihydro(2H)-naphthalen-1-one-O-[(4-methylphenyl)sulfonyl]oxime 
• 6836-19-7 7-Methoxy-1-tetralone 
• 22009-38-7 7-hydroxy-1-tetralone 
• 32263-64-2 7-(benzyloxy)-3,4-dihydronaphthalen-1(2H)-one 
• 116885-91-7 7-benzyloxy-3,4-dihydro-2H-naphthalen-1-one oxime 

Downstream Products

• 1034706-81-4 (+)-N-acetyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazine-9-ol triisopropylsilyl ether 
• 2451-66-3 trans-2-amino-7-benzoxy-1-tetraol 
• 2451-66-3 (1S,2R)-2-Amino-7-benzyloxy-1,2,3,4-tetrahydro-naphthalen-1-ol 

Relevant academic research and scientific papers

Synthesis of the dopamine D2/D3 receptor agonist (+)-PHNO via supercritical fluid chromatography: Preliminary PET imaging study with [3-11C]-(+)PHNO

Carbon-11 labeled (+)-4-[1-11C]propyl-3,4,4a,5,6,10b-hexahydro- 2H-naphtho[1,2-b][1,4]oxazin-9-ol ([1-11C]-(+)-PHNO) is a dopamine D3-preferring agonist radiopharmaceutical used for medical imaging by positron emission tomography (PET). We report the synthesis of (+)-PHNO using supercritical fluid chromatography for enantiomeric resolution of its norpropyl derivative, HNO, followed by propylation. (+)-HNO was used to prepare the radiolabeling precursor, (+)-trans-4-acetyl-9-triisopropylsilyloxy-2,3,4a,5,6, 10b-hexahydro-4H-naphth[1,2b][1,4]oxazine, in 12 steps. Modifications to the labeling procedure were made to ensure consistent preparation of [3- 11C]-(+)-PHNO via [11C]CH3I. A preliminary PET imaging study was carried out with this tracer in an attempt to image dopamine receptors in brown adipose tissue (brown fat) in vivo.